FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP)...
December 22, 2021
by FDA
Black, Hispanic/Latino MSM Less Likely to Have HIV Diagnosis
Black and Hispanic/Latino men who have sex with men (MSM) are less likely than White MSM to receive an HIV diagnosis or use preexposure prophylaxis (PrEP)...
December 14, 2021
by Drugs
Merck Pauses Enrollment for Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis of HIV-1 infection
Merck announced a pause in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591-024) Phase 3 clinical studies evaluating investigational, once-monthly, oral islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor...
December 9, 2021
by AmericanPharmaceuticalReview
PrEP HIV Prevention Pills to Be Free for Insured Americans
Nearly all health insurers must cover the entire cost of HIV prevention treatments, the U.S. government says. That includes the two approved pre-exposure prophylaxis(PrEP) drugs Truvada and Descovy, all clinic visits, and lab tests, NBC News reported.
July 22, 2021
by drugs
Trial of new HIV PrEP medication stopped early due to effectiveness
The trial was stopped because the data suggested that injections of the long-acting antiretroviral drug cabotegravir (CAB LA) are highly effective for HIV pre-exposure prophylaxis (PrEP) in women.
November 13, 2020
by europeanpharmaceuticalreview
Long-acting injectable HIV PrEP outperforms commercially available daily pill
Extensive analysis of interim data finds patients given cabotegravir injection had a 66 percent lower incidence of HIV acquisition than those taking Truvada pills.
July 9, 2020
by europeanpharmaceuticalreview
PrEP to be available in England from April
From April, the Department of Health and Social Care will ensure that everyone at high risk of contracting HIV will receive PrEP from their local sexual health clinic.
March 18, 2020
by pharmatimes
Minor Changes in BMD Seen With Tenofovir PrEP in Short Term
Tenofovir preexposure prophylaxis (PrEP) therapy does not appear to be associated with clinically significant declines in bone mineral density (BMD) in the short term...
July 26, 2019
by drugs
Awareness, Use of PrEP on Rise Among Men Who Have Sex With Men
Awareness, Use of PrEP on Rise Among Men Who Have Sex With Men.
July 12, 2019
by drugs
Two Algorithms Can ID Patients at Risk for HIV, PrEP Candidates
Two new research papers, published online in The Lancet HIV, present algorithms that can help identify patients at risk for HIV and candidates for preexposure prophylaxis (PrEP).
July 11, 2019
by drugs
USPSTF Issues Recommendations on HIV Screening, Prevention
USPSTF Issues Recommendations on HIV Screening, Prevention.
June 12, 2019
by drugs
Generic Version of Truvada Available in U.S. by Sept. 2020
Generic Version of Truvada Available in U.S. by Sept. 2020.
May 10, 2019
by drugs